GlassScriptPhysician profile
Michael L Otto
NPI 1639168891
$2,093.22
in general payments reported to CMS, 2019-2025
28 companies · $34.54 in 2025
The $34.54 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $993 · 2022: $426 · 2023: $443 · 2024: $196 · 2025: $34.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $213.31 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $203.86 | 2021-2022 | |
| Amgen INC. | $196.47 | 2021-2023 | Repatha |
| Merck Sharp & Dohme LLC | $140.94 | 2021-2023 | Verquvo |
| Abbott Laboratories | $128.75 | 2021-2023 | Cardiomems, Mitraclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $125.73 | 2021-2024 | Lifevest |
| Astellas Pharma US INC | $112.07 | 2021 | |
| W. L. Gore & Associates, INC. | $101.12 | 2021 | |
| Medtronic, INC. | $97.90 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.98 | 2021-2023 | Jardiance |
| Cvrx, INC. | $85.38 | 2023-2024 | Barostim Neo System |
| Abiomed | $81.79 | 2022-2024 | Impella |
| Actelion Pharmaceuticals US, INC. | $76.25 | 2021-2023 | Uptravi, Opsumit |
| Amarin Pharma, INC. | $69.48 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $57.28 | 2022-2023 | Camzyos |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $47.70 | 2023 | Inpefa |
| Pfizer INC. | $41.06 | 2021-2023 | |
| Philips North America LLC | $32.00 | 2022-2024 | (Ck4) Mcot |
| Esperion Therapeutics, INC. | $31.26 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.93 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $24.58 | 2022-2023 | |
| Solventum Corporation | $20.49 | 2025 | Prevena, V.A.C. Veraflo Cleanse Choice |
| Terumo Medical Corporation | $20.18 | 2024 | Tr Band, Glidewire, Navicross |
| Xeris Pharmaceuticals, INC. | $17.12 | 2023 | Gvoke Hypopen |
| Cardiovascular Systems INC. | $15.20 | 2022 | |
| Boston Scientific Corporation | $14.05 | 2025 | Cds - Mct/Cem Monitoring |
| Arbor Pharmaceuticals, INC. | $12.68 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Otto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.